nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—VEGFA—psoriasis	0.391	1	CbGaD
Vandetanib—ALB—Acitretin—psoriasis	0.0314	0.137	CbGbCtD
Vandetanib—ABCC1—Cyclosporine—psoriasis	0.0241	0.106	CbGbCtD
Vandetanib—ABCG2—Mycophenolate mofetil—psoriasis	0.0213	0.0934	CbGbCtD
Vandetanib—ABCG2—Hydrocortisone—psoriasis	0.0171	0.0749	CbGbCtD
Vandetanib—ABCG2—Cyclosporine—psoriasis	0.0162	0.0708	CbGbCtD
Vandetanib—ALB—Mycophenolate mofetil—psoriasis	0.0147	0.0644	CbGbCtD
Vandetanib—ABCC1—Methotrexate—psoriasis	0.0128	0.056	CbGbCtD
Vandetanib—FMO3—sweat—psoriasis	0.0126	0.205	CbGeAlD
Vandetanib—ALB—Prednisone—psoriasis	0.0117	0.0515	CbGbCtD
Vandetanib—ABCG2—Dexamethasone—psoriasis	0.0106	0.0466	CbGbCtD
Vandetanib—CYP3A4—Calcitriol—psoriasis	0.0103	0.0452	CbGbCtD
Vandetanib—ABCG2—Methotrexate—psoriasis	0.00855	0.0375	CbGbCtD
Vandetanib—CYP3A4—Methoxsalen—psoriasis	0.00802	0.0351	CbGbCtD
Vandetanib—ALB—Methotrexate—psoriasis	0.00589	0.0258	CbGbCtD
Vandetanib—PTK6—skin epidermis—psoriasis	0.00571	0.0929	CbGeAlD
Vandetanib—CYP3A4—Cholecalciferol—psoriasis	0.00531	0.0233	CbGbCtD
Vandetanib—RIPK2—synovial membrane of synovial joint—psoriasis	0.00529	0.0861	CbGeAlD
Vandetanib—CYP3A4—Triamcinolone—psoriasis	0.00461	0.0202	CbGbCtD
Vandetanib—CYP3A4—Mycophenolate mofetil—psoriasis	0.00461	0.0202	CbGbCtD
Vandetanib—CYP3A4—Betamethasone—psoriasis	0.00395	0.0173	CbGbCtD
Vandetanib—CYP3A4—Prednisolone—psoriasis	0.0039	0.0171	CbGbCtD
Vandetanib—CYP3A4—Hydrocortisone—psoriasis	0.0037	0.0162	CbGbCtD
Vandetanib—CYP3A4—Prednisone—psoriasis	0.00368	0.0161	CbGbCtD
Vandetanib—CYP3A4—Cyclosporine—psoriasis	0.00349	0.0153	CbGbCtD
Vandetanib—ORM1—vertebral column—psoriasis	0.00297	0.0483	CbGeAlD
Vandetanib—FLT4—endothelium—psoriasis	0.00248	0.0403	CbGeAlD
Vandetanib—RIPK2—endothelium—psoriasis	0.00246	0.0401	CbGeAlD
Vandetanib—CYP3A4—Dexamethasone—psoriasis	0.0023	0.0101	CbGbCtD
Vandetanib—TEK—endothelium—psoriasis	0.00199	0.0324	CbGeAlD
Vandetanib—PTK6—skin of body—psoriasis	0.00177	0.0288	CbGeAlD
Vandetanib—SRC—endothelium—psoriasis	0.00177	0.0288	CbGeAlD
Vandetanib—KDR—endothelium—psoriasis	0.00163	0.0265	CbGeAlD
Vandetanib—TYRO3—skin of body—psoriasis	0.00137	0.0223	CbGeAlD
Vandetanib—STK35—skin of body—psoriasis	0.00114	0.0186	CbGeAlD
Vandetanib—RIPK2—skin of body—psoriasis	0.00105	0.0171	CbGeAlD
Vandetanib—ERBB3—skin of body—psoriasis	0.00101	0.0164	CbGeAlD
Vandetanib—AXL—skin of body—psoriasis	0.00093	0.0151	CbGeAlD
Vandetanib—FYN—skin of body—psoriasis	0.00087	0.0142	CbGeAlD
Vandetanib—STK35—tendon—psoriasis	0.000868	0.0141	CbGeAlD
Vandetanib—ABL2—tendon—psoriasis	0.000846	0.0138	CbGeAlD
Vandetanib—EPHB6—skin of body—psoriasis	0.000813	0.0132	CbGeAlD
Vandetanib—RIPK2—tendon—psoriasis	0.000801	0.013	CbGeAlD
Vandetanib—VEGFA—tendon—psoriasis	0.000799	0.013	CbGeAlD
Vandetanib—FMO1—tendon—psoriasis	0.000794	0.0129	CbGeAlD
Vandetanib—IRAK4—tendon—psoriasis	0.000782	0.0127	CbGeAlD
Vandetanib—SRC—skin of body—psoriasis	0.000756	0.0123	CbGeAlD
Vandetanib—FGR—tendon—psoriasis	0.000711	0.0116	CbGeAlD
Vandetanib—RET—tendon—psoriasis	0.000711	0.0116	CbGeAlD
Vandetanib—AXL—tendon—psoriasis	0.000708	0.0115	CbGeAlD
Vandetanib—SLK—tendon—psoriasis	0.000681	0.0111	CbGeAlD
Vandetanib—FYN—tendon—psoriasis	0.000663	0.0108	CbGeAlD
Vandetanib—MAP4K5—tendon—psoriasis	0.000647	0.0105	CbGeAlD
Vandetanib—TEK—tendon—psoriasis	0.000647	0.0105	CbGeAlD
Vandetanib—EPHB6—tendon—psoriasis	0.000619	0.0101	CbGeAlD
Vandetanib—PDGFRB—skin of body—psoriasis	0.000602	0.00979	CbGeAlD
Vandetanib—YES1—tendon—psoriasis	0.000598	0.00973	CbGeAlD
Vandetanib—STK10—tendon—psoriasis	0.000593	0.00964	CbGeAlD
Vandetanib—ABL1—skin of body—psoriasis	0.000536	0.00872	CbGeAlD
Vandetanib—MAP2K5—tendon—psoriasis	0.000529	0.00861	CbGeAlD
Vandetanib—KDR—tendon—psoriasis	0.000529	0.00861	CbGeAlD
Vandetanib—PDGFRB—tendon—psoriasis	0.000458	0.00745	CbGeAlD
Vandetanib—ABL1—tendon—psoriasis	0.000408	0.00664	CbGeAlD
Vandetanib—ABCC1—tendon—psoriasis	0.000311	0.00506	CbGeAlD
Vandetanib—VEGFA—Dexamethasone—Clobetasol propionate—psoriasis	0.000272	0.0969	CbGdCrCtD
Vandetanib—VEGFA—Betamethasone—Clobetasol propionate—psoriasis	0.000272	0.0969	CbGdCrCtD
Vandetanib—VEGFA—Betamethasone—Beclomethasone—psoriasis	0.000218	0.0776	CbGdCrCtD
Vandetanib—VEGFA—Betamethasone—Fluocinonide—psoriasis	0.000218	0.0776	CbGdCrCtD
Vandetanib—VEGFA—Dexamethasone—Fluocinonide—psoriasis	0.000218	0.0776	CbGdCrCtD
Vandetanib—VEGFA—Dexamethasone—Beclomethasone—psoriasis	0.000218	0.0776	CbGdCrCtD
Vandetanib—VEGFA—Dexamethasone—Fluocinolone Acetonide—psoriasis	0.000211	0.0754	CbGdCrCtD
Vandetanib—VEGFA—Betamethasone—Fluocinolone Acetonide—psoriasis	0.000211	0.0754	CbGdCrCtD
Vandetanib—VEGFA—Betamethasone—Hydrocortisone—psoriasis	0.000107	0.0381	CbGdCrCtD
Vandetanib—VEGFA—Dexamethasone—Hydrocortisone—psoriasis	0.000107	0.0381	CbGdCrCtD
Vandetanib—VEGFA—Dexamethasone—Betamethasone—psoriasis	9.92e-05	0.0354	CbGdCrCtD
Vandetanib—VEGFA—Betamethasone—Dexamethasone—psoriasis	9.92e-05	0.0354	CbGdCrCtD
Vandetanib—VEGFA—Dexamethasone—Triamcinolone—psoriasis	9.69e-05	0.0345	CbGdCrCtD
Vandetanib—VEGFA—Betamethasone—Triamcinolone—psoriasis	9.69e-05	0.0345	CbGdCrCtD
Vandetanib—VEGFA—Dexamethasone—Prednisone—psoriasis	9.2e-05	0.0328	CbGdCrCtD
Vandetanib—VEGFA—Betamethasone—Prednisone—psoriasis	9.2e-05	0.0328	CbGdCrCtD
Vandetanib—VEGFA—Dexamethasone—Prednisolone—psoriasis	8.98e-05	0.032	CbGdCrCtD
Vandetanib—VEGFA—Betamethasone—Prednisolone—psoriasis	8.98e-05	0.032	CbGdCrCtD
Vandetanib—Oedema—Hydrocortisone—psoriasis	6.88e-05	0.000386	CcSEcCtD
Vandetanib—Convulsion—Triamcinolone—psoriasis	6.87e-05	0.000386	CcSEcCtD
Vandetanib—Photosensitivity reaction—Methotrexate—psoriasis	6.86e-05	0.000385	CcSEcCtD
Vandetanib—Asthenia—Mycophenolic acid—psoriasis	6.86e-05	0.000385	CcSEcCtD
Vandetanib—Hypertension—Triamcinolone—psoriasis	6.85e-05	0.000385	CcSEcCtD
Vandetanib—Infection—Hydrocortisone—psoriasis	6.83e-05	0.000384	CcSEcCtD
Vandetanib—Insomnia—Mycophenolate mofetil—psoriasis	6.83e-05	0.000383	CcSEcCtD
Vandetanib—Dyspepsia—Cyclosporine—psoriasis	6.81e-05	0.000382	CcSEcCtD
Vandetanib—Nausea—Hydroxyurea—psoriasis	6.78e-05	0.000381	CcSEcCtD
Vandetanib—Paraesthesia—Mycophenolate mofetil—psoriasis	6.78e-05	0.000381	CcSEcCtD
Vandetanib—Pruritus—Mycophenolic acid—psoriasis	6.77e-05	0.00038	CcSEcCtD
Vandetanib—Nervous system disorder—Hydrocortisone—psoriasis	6.74e-05	0.000379	CcSEcCtD
Vandetanib—Pneumonia—Methotrexate—psoriasis	6.74e-05	0.000379	CcSEcCtD
Vandetanib—Eye disorder—Prednisone—psoriasis	6.73e-05	0.000378	CcSEcCtD
Vandetanib—Dyspnoea—Mycophenolate mofetil—psoriasis	6.73e-05	0.000378	CcSEcCtD
Vandetanib—Decreased appetite—Cyclosporine—psoriasis	6.73e-05	0.000378	CcSEcCtD
Vandetanib—Infestation—Methotrexate—psoriasis	6.7e-05	0.000376	CcSEcCtD
Vandetanib—Infestation NOS—Methotrexate—psoriasis	6.7e-05	0.000376	CcSEcCtD
Vandetanib—Depression—Methotrexate—psoriasis	6.69e-05	0.000375	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Cyclosporine—psoriasis	6.68e-05	0.000375	CcSEcCtD
Vandetanib—Skin disorder—Hydrocortisone—psoriasis	6.68e-05	0.000375	CcSEcCtD
Vandetanib—Fatigue—Cyclosporine—psoriasis	6.67e-05	0.000375	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Methotrexate—psoriasis	6.65e-05	0.000373	CcSEcCtD
Vandetanib—Dyspepsia—Mycophenolate mofetil—psoriasis	6.64e-05	0.000373	CcSEcCtD
Vandetanib—Pain—Cyclosporine—psoriasis	6.62e-05	0.000372	CcSEcCtD
Vandetanib—Constipation—Cyclosporine—psoriasis	6.62e-05	0.000372	CcSEcCtD
Vandetanib—Dry mouth—Triamcinolone—psoriasis	6.61e-05	0.000371	CcSEcCtD
Vandetanib—Renal failure—Methotrexate—psoriasis	6.59e-05	0.00037	CcSEcCtD
Vandetanib—Decreased appetite—Mycophenolate mofetil—psoriasis	6.56e-05	0.000368	CcSEcCtD
Vandetanib—Diarrhoea—Mycophenolic acid—psoriasis	6.54e-05	0.000367	CcSEcCtD
Vandetanib—Stomatitis—Methotrexate—psoriasis	6.54e-05	0.000367	CcSEcCtD
Vandetanib—Angiopathy—Prednisone—psoriasis	6.53e-05	0.000367	CcSEcCtD
Vandetanib—Conjunctivitis—Methotrexate—psoriasis	6.52e-05	0.000366	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	6.52e-05	0.000366	CcSEcCtD
Vandetanib—Oedema—Triamcinolone—psoriasis	6.48e-05	0.000364	CcSEcCtD
Vandetanib—Constipation—Mycophenolate mofetil—psoriasis	6.45e-05	0.000362	CcSEcCtD
Vandetanib—Pain—Mycophenolate mofetil—psoriasis	6.45e-05	0.000362	CcSEcCtD
Vandetanib—Arrhythmia—Prednisone—psoriasis	6.43e-05	0.000361	CcSEcCtD
Vandetanib—Infection—Triamcinolone—psoriasis	6.43e-05	0.000361	CcSEcCtD
Vandetanib—Haematuria—Methotrexate—psoriasis	6.39e-05	0.000359	CcSEcCtD
Vandetanib—Insomnia—Prednisolone—psoriasis	6.37e-05	0.000358	CcSEcCtD
Vandetanib—Alopecia—Prednisone—psoriasis	6.36e-05	0.000357	CcSEcCtD
Vandetanib—Hepatobiliary disease—Methotrexate—psoriasis	6.34e-05	0.000356	CcSEcCtD
Vandetanib—Gastrointestinal pain—Cyclosporine—psoriasis	6.33e-05	0.000355	CcSEcCtD
Vandetanib—Loss of consciousness—Betamethasone—psoriasis	6.33e-05	0.000355	CcSEcCtD
Vandetanib—Loss of consciousness—Dexamethasone—psoriasis	6.33e-05	0.000355	CcSEcCtD
Vandetanib—Dizziness—Mycophenolic acid—psoriasis	6.32e-05	0.000355	CcSEcCtD
Vandetanib—Epistaxis—Methotrexate—psoriasis	6.32e-05	0.000355	CcSEcCtD
Vandetanib—Paraesthesia—Prednisolone—psoriasis	6.32e-05	0.000355	CcSEcCtD
Vandetanib—Mental disorder—Prednisone—psoriasis	6.31e-05	0.000354	CcSEcCtD
Vandetanib—Malnutrition—Prednisone—psoriasis	6.27e-05	0.000352	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Hydrocortisone—psoriasis	6.27e-05	0.000352	CcSEcCtD
Vandetanib—Convulsion—Dexamethasone—psoriasis	6.24e-05	0.00035	CcSEcCtD
Vandetanib—Convulsion—Betamethasone—psoriasis	6.24e-05	0.00035	CcSEcCtD
Vandetanib—Insomnia—Hydrocortisone—psoriasis	6.22e-05	0.000349	CcSEcCtD
Vandetanib—Hypertension—Dexamethasone—psoriasis	6.22e-05	0.000349	CcSEcCtD
Vandetanib—Hypertension—Betamethasone—psoriasis	6.22e-05	0.000349	CcSEcCtD
Vandetanib—Paraesthesia—Hydrocortisone—psoriasis	6.17e-05	0.000347	CcSEcCtD
Vandetanib—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	6.17e-05	0.000347	CcSEcCtD
Vandetanib—Abdominal pain—Cyclosporine—psoriasis	6.12e-05	0.000343	CcSEcCtD
Vandetanib—Body temperature increased—Cyclosporine—psoriasis	6.12e-05	0.000343	CcSEcCtD
Vandetanib—Anxiety—Dexamethasone—psoriasis	6.11e-05	0.000343	CcSEcCtD
Vandetanib—Anxiety—Betamethasone—psoriasis	6.11e-05	0.000343	CcSEcCtD
Vandetanib—Vomiting—Mycophenolic acid—psoriasis	6.08e-05	0.000341	CcSEcCtD
Vandetanib—Dyspepsia—Hydrocortisone—psoriasis	6.05e-05	0.00034	CcSEcCtD
Vandetanib—Haemoglobin—Methotrexate—psoriasis	6.05e-05	0.00034	CcSEcCtD
Vandetanib—Rash—Mycophenolic acid—psoriasis	6.03e-05	0.000339	CcSEcCtD
Vandetanib—Dermatitis—Mycophenolic acid—psoriasis	6.02e-05	0.000338	CcSEcCtD
Vandetanib—Pain—Prednisolone—psoriasis	6.02e-05	0.000338	CcSEcCtD
Vandetanib—Haemorrhage—Methotrexate—psoriasis	6.02e-05	0.000338	CcSEcCtD
Vandetanib—Headache—Mycophenolic acid—psoriasis	5.99e-05	0.000336	CcSEcCtD
Vandetanib—Decreased appetite—Hydrocortisone—psoriasis	5.98e-05	0.000336	CcSEcCtD
Vandetanib—Abdominal pain—Mycophenolate mofetil—psoriasis	5.97e-05	0.000335	CcSEcCtD
Vandetanib—Body temperature increased—Mycophenolate mofetil—psoriasis	5.97e-05	0.000335	CcSEcCtD
Vandetanib—Urinary tract disorder—Methotrexate—psoriasis	5.94e-05	0.000334	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Hydrocortisone—psoriasis	5.94e-05	0.000333	CcSEcCtD
Vandetanib—Fatigue—Hydrocortisone—psoriasis	5.93e-05	0.000333	CcSEcCtD
Vandetanib—Vision blurred—Prednisone—psoriasis	5.91e-05	0.000332	CcSEcCtD
Vandetanib—Urethral disorder—Methotrexate—psoriasis	5.9e-05	0.000331	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Triamcinolone—psoriasis	5.9e-05	0.000331	CcSEcCtD
Vandetanib—Pain—Hydrocortisone—psoriasis	5.88e-05	0.00033	CcSEcCtD
Vandetanib—Oedema—Betamethasone—psoriasis	5.88e-05	0.00033	CcSEcCtD
Vandetanib—Oedema—Dexamethasone—psoriasis	5.88e-05	0.00033	CcSEcCtD
Vandetanib—Insomnia—Triamcinolone—psoriasis	5.86e-05	0.000329	CcSEcCtD
Vandetanib—Infection—Betamethasone—psoriasis	5.84e-05	0.000328	CcSEcCtD
Vandetanib—Infection—Dexamethasone—psoriasis	5.84e-05	0.000328	CcSEcCtD
Vandetanib—Paraesthesia—Triamcinolone—psoriasis	5.81e-05	0.000326	CcSEcCtD
Vandetanib—Visual impairment—Methotrexate—psoriasis	5.8e-05	0.000326	CcSEcCtD
Vandetanib—Dyspnoea—Triamcinolone—psoriasis	5.77e-05	0.000324	CcSEcCtD
Vandetanib—Nervous system disorder—Dexamethasone—psoriasis	5.76e-05	0.000324	CcSEcCtD
Vandetanib—Nervous system disorder—Betamethasone—psoriasis	5.76e-05	0.000324	CcSEcCtD
Vandetanib—Thrombocytopenia—Dexamethasone—psoriasis	5.75e-05	0.000323	CcSEcCtD
Vandetanib—Thrombocytopenia—Betamethasone—psoriasis	5.75e-05	0.000323	CcSEcCtD
Vandetanib—Dyspepsia—Triamcinolone—psoriasis	5.7e-05	0.00032	CcSEcCtD
Vandetanib—Erythema multiforme—Methotrexate—psoriasis	5.69e-05	0.00032	CcSEcCtD
Vandetanib—Nausea—Mycophenolic acid—psoriasis	5.68e-05	0.000319	CcSEcCtD
Vandetanib—Eye disorder—Methotrexate—psoriasis	5.62e-05	0.000316	CcSEcCtD
Vandetanib—Gastrointestinal pain—Hydrocortisone—psoriasis	5.62e-05	0.000316	CcSEcCtD
Vandetanib—Cardiac disorder—Methotrexate—psoriasis	5.59e-05	0.000314	CcSEcCtD
Vandetanib—Fatigue—Triamcinolone—psoriasis	5.58e-05	0.000313	CcSEcCtD
Vandetanib—Asthenia—Cyclosporine—psoriasis	5.55e-05	0.000312	CcSEcCtD
Vandetanib—Pain—Triamcinolone—psoriasis	5.54e-05	0.000311	CcSEcCtD
Vandetanib—Loss of consciousness—Prednisone—psoriasis	5.51e-05	0.000309	CcSEcCtD
Vandetanib—Pruritus—Cyclosporine—psoriasis	5.47e-05	0.000307	CcSEcCtD
Vandetanib—Angiopathy—Methotrexate—psoriasis	5.46e-05	0.000307	CcSEcCtD
Vandetanib—Abdominal pain—Hydrocortisone—psoriasis	5.44e-05	0.000305	CcSEcCtD
Vandetanib—Body temperature increased—Hydrocortisone—psoriasis	5.44e-05	0.000305	CcSEcCtD
Vandetanib—Convulsion—Prednisone—psoriasis	5.43e-05	0.000305	CcSEcCtD
Vandetanib—Mediastinal disorder—Methotrexate—psoriasis	5.42e-05	0.000305	CcSEcCtD
Vandetanib—Asthenia—Mycophenolate mofetil—psoriasis	5.42e-05	0.000304	CcSEcCtD
Vandetanib—Hypertension—Prednisone—psoriasis	5.41e-05	0.000304	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Dexamethasone—psoriasis	5.35e-05	0.000301	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Betamethasone—psoriasis	5.35e-05	0.000301	CcSEcCtD
Vandetanib—Pruritus—Mycophenolate mofetil—psoriasis	5.34e-05	0.0003	CcSEcCtD
Vandetanib—Arthralgia—Prednisone—psoriasis	5.34e-05	0.0003	CcSEcCtD
Vandetanib—Anxiety—Prednisone—psoriasis	5.32e-05	0.000299	CcSEcCtD
Vandetanib—Alopecia—Methotrexate—psoriasis	5.32e-05	0.000299	CcSEcCtD
Vandetanib—Insomnia—Dexamethasone—psoriasis	5.31e-05	0.000298	CcSEcCtD
Vandetanib—Insomnia—Betamethasone—psoriasis	5.31e-05	0.000298	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	5.3e-05	0.000298	CcSEcCtD
Vandetanib—Diarrhoea—Cyclosporine—psoriasis	5.29e-05	0.000297	CcSEcCtD
Vandetanib—Paraesthesia—Dexamethasone—psoriasis	5.28e-05	0.000296	CcSEcCtD
Vandetanib—Paraesthesia—Betamethasone—psoriasis	5.28e-05	0.000296	CcSEcCtD
Vandetanib—Mental disorder—Methotrexate—psoriasis	5.27e-05	0.000296	CcSEcCtD
Vandetanib—Malnutrition—Methotrexate—psoriasis	5.24e-05	0.000294	CcSEcCtD
Vandetanib—Dyspepsia—Betamethasone—psoriasis	5.17e-05	0.00029	CcSEcCtD
Vandetanib—Dyspepsia—Dexamethasone—psoriasis	5.17e-05	0.00029	CcSEcCtD
Vandetanib—Diarrhoea—Mycophenolate mofetil—psoriasis	5.16e-05	0.00029	CcSEcCtD
Vandetanib—Dysgeusia—Methotrexate—psoriasis	5.13e-05	0.000288	CcSEcCtD
Vandetanib—Body temperature increased—Triamcinolone—psoriasis	5.12e-05	0.000287	CcSEcCtD
Vandetanib—Dizziness—Cyclosporine—psoriasis	5.12e-05	0.000287	CcSEcCtD
Vandetanib—Oedema—Prednisone—psoriasis	5.12e-05	0.000287	CcSEcCtD
Vandetanib—Decreased appetite—Dexamethasone—psoriasis	5.11e-05	0.000287	CcSEcCtD
Vandetanib—Decreased appetite—Betamethasone—psoriasis	5.11e-05	0.000287	CcSEcCtD
Vandetanib—Infection—Prednisone—psoriasis	5.08e-05	0.000285	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Betamethasone—psoriasis	5.07e-05	0.000285	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Dexamethasone—psoriasis	5.07e-05	0.000285	CcSEcCtD
Vandetanib—Fatigue—Betamethasone—psoriasis	5.07e-05	0.000284	CcSEcCtD
Vandetanib—Fatigue—Dexamethasone—psoriasis	5.07e-05	0.000284	CcSEcCtD
Vandetanib—Pain—Dexamethasone—psoriasis	5.02e-05	0.000282	CcSEcCtD
Vandetanib—Pain—Betamethasone—psoriasis	5.02e-05	0.000282	CcSEcCtD
Vandetanib—Nervous system disorder—Prednisone—psoriasis	5.02e-05	0.000282	CcSEcCtD
Vandetanib—Dizziness—Mycophenolate mofetil—psoriasis	4.99e-05	0.00028	CcSEcCtD
Vandetanib—Skin disorder—Prednisone—psoriasis	4.97e-05	0.000279	CcSEcCtD
Vandetanib—Vision blurred—Methotrexate—psoriasis	4.94e-05	0.000277	CcSEcCtD
Vandetanib—Asthenia—Hydrocortisone—psoriasis	4.93e-05	0.000277	CcSEcCtD
Vandetanib—Vomiting—Cyclosporine—psoriasis	4.92e-05	0.000276	CcSEcCtD
Vandetanib—Rash—Cyclosporine—psoriasis	4.88e-05	0.000274	CcSEcCtD
Vandetanib—Dermatitis—Cyclosporine—psoriasis	4.87e-05	0.000274	CcSEcCtD
Vandetanib—Pruritus—Hydrocortisone—psoriasis	4.87e-05	0.000273	CcSEcCtD
Vandetanib—Headache—Cyclosporine—psoriasis	4.85e-05	0.000272	CcSEcCtD
Vandetanib—Gastrointestinal pain—Betamethasone—psoriasis	4.8e-05	0.00027	CcSEcCtD
Vandetanib—Gastrointestinal pain—Dexamethasone—psoriasis	4.8e-05	0.00027	CcSEcCtD
Vandetanib—Vomiting—Mycophenolate mofetil—psoriasis	4.8e-05	0.000269	CcSEcCtD
Vandetanib—Rash—Mycophenolate mofetil—psoriasis	4.76e-05	0.000267	CcSEcCtD
Vandetanib—Dermatitis—Mycophenolate mofetil—psoriasis	4.75e-05	0.000267	CcSEcCtD
Vandetanib—Headache—Mycophenolate mofetil—psoriasis	4.73e-05	0.000266	CcSEcCtD
Vandetanib—Diarrhoea—Hydrocortisone—psoriasis	4.71e-05	0.000264	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Prednisone—psoriasis	4.66e-05	0.000262	CcSEcCtD
Vandetanib—Dizziness—Prednisolone—psoriasis	4.66e-05	0.000261	CcSEcCtD
Vandetanib—Asthenia—Triamcinolone—psoriasis	4.65e-05	0.000261	CcSEcCtD
Vandetanib—Body temperature increased—Dexamethasone—psoriasis	4.64e-05	0.000261	CcSEcCtD
Vandetanib—Abdominal pain—Dexamethasone—psoriasis	4.64e-05	0.000261	CcSEcCtD
Vandetanib—Abdominal pain—Betamethasone—psoriasis	4.64e-05	0.000261	CcSEcCtD
Vandetanib—Body temperature increased—Betamethasone—psoriasis	4.64e-05	0.000261	CcSEcCtD
Vandetanib—Insomnia—Prednisone—psoriasis	4.63e-05	0.00026	CcSEcCtD
Vandetanib—Nausea—Cyclosporine—psoriasis	4.6e-05	0.000258	CcSEcCtD
Vandetanib—Paraesthesia—Prednisone—psoriasis	4.59e-05	0.000258	CcSEcCtD
Vandetanib—Pruritus—Triamcinolone—psoriasis	4.58e-05	0.000257	CcSEcCtD
Vandetanib—Cough—Methotrexate—psoriasis	4.57e-05	0.000257	CcSEcCtD
Vandetanib—Dizziness—Hydrocortisone—psoriasis	4.55e-05	0.000255	CcSEcCtD
Vandetanib—Convulsion—Methotrexate—psoriasis	4.54e-05	0.000255	CcSEcCtD
Vandetanib—Dyspepsia—Prednisone—psoriasis	4.5e-05	0.000253	CcSEcCtD
Vandetanib—Nausea—Mycophenolate mofetil—psoriasis	4.48e-05	0.000252	CcSEcCtD
Vandetanib—Chest pain—Methotrexate—psoriasis	4.46e-05	0.00025	CcSEcCtD
Vandetanib—Arthralgia—Methotrexate—psoriasis	4.46e-05	0.00025	CcSEcCtD
Vandetanib—Decreased appetite—Prednisone—psoriasis	4.45e-05	0.00025	CcSEcCtD
Vandetanib—Rash—Prednisolone—psoriasis	4.44e-05	0.000249	CcSEcCtD
Vandetanib—Dermatitis—Prednisolone—psoriasis	4.44e-05	0.000249	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	4.43e-05	0.000249	CcSEcCtD
Vandetanib—Fatigue—Prednisone—psoriasis	4.41e-05	0.000248	CcSEcCtD
Vandetanib—Headache—Prednisolone—psoriasis	4.41e-05	0.000248	CcSEcCtD
Vandetanib—Constipation—Prednisone—psoriasis	4.38e-05	0.000246	CcSEcCtD
Vandetanib—Vomiting—Hydrocortisone—psoriasis	4.37e-05	0.000246	CcSEcCtD
Vandetanib—Rash—Hydrocortisone—psoriasis	4.34e-05	0.000243	CcSEcCtD
Vandetanib—Dermatitis—Hydrocortisone—psoriasis	4.33e-05	0.000243	CcSEcCtD
Vandetanib—Headache—Hydrocortisone—psoriasis	4.31e-05	0.000242	CcSEcCtD
Vandetanib—Dizziness—Triamcinolone—psoriasis	4.28e-05	0.00024	CcSEcCtD
Vandetanib—Infection—Methotrexate—psoriasis	4.25e-05	0.000239	CcSEcCtD
Vandetanib—Asthenia—Dexamethasone—psoriasis	4.22e-05	0.000237	CcSEcCtD
Vandetanib—Asthenia—Betamethasone—psoriasis	4.22e-05	0.000237	CcSEcCtD
Vandetanib—Nervous system disorder—Methotrexate—psoriasis	4.19e-05	0.000235	CcSEcCtD
Vandetanib—Thrombocytopenia—Methotrexate—psoriasis	4.19e-05	0.000235	CcSEcCtD
Vandetanib—Gastrointestinal pain—Prednisone—psoriasis	4.18e-05	0.000235	CcSEcCtD
Vandetanib—Nausea—Prednisolone—psoriasis	4.18e-05	0.000235	CcSEcCtD
Vandetanib—Pruritus—Dexamethasone—psoriasis	4.16e-05	0.000233	CcSEcCtD
Vandetanib—Pruritus—Betamethasone—psoriasis	4.16e-05	0.000233	CcSEcCtD
Vandetanib—Skin disorder—Methotrexate—psoriasis	4.15e-05	0.000233	CcSEcCtD
Vandetanib—Vomiting—Triamcinolone—psoriasis	4.12e-05	0.000231	CcSEcCtD
Vandetanib—Nausea—Hydrocortisone—psoriasis	4.08e-05	0.000229	CcSEcCtD
Vandetanib—Rash—Triamcinolone—psoriasis	4.08e-05	0.000229	CcSEcCtD
Vandetanib—Dermatitis—Triamcinolone—psoriasis	4.08e-05	0.000229	CcSEcCtD
Vandetanib—Headache—Triamcinolone—psoriasis	4.06e-05	0.000228	CcSEcCtD
Vandetanib—Abdominal pain—Prednisone—psoriasis	4.04e-05	0.000227	CcSEcCtD
Vandetanib—Body temperature increased—Prednisone—psoriasis	4.04e-05	0.000227	CcSEcCtD
Vandetanib—Diarrhoea—Betamethasone—psoriasis	4.02e-05	0.000226	CcSEcCtD
Vandetanib—Diarrhoea—Dexamethasone—psoriasis	4.02e-05	0.000226	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Methotrexate—psoriasis	3.9e-05	0.000219	CcSEcCtD
Vandetanib—Dizziness—Betamethasone—psoriasis	3.89e-05	0.000218	CcSEcCtD
Vandetanib—Dizziness—Dexamethasone—psoriasis	3.89e-05	0.000218	CcSEcCtD
Vandetanib—Insomnia—Methotrexate—psoriasis	3.87e-05	0.000217	CcSEcCtD
Vandetanib—Nausea—Triamcinolone—psoriasis	3.85e-05	0.000216	CcSEcCtD
Vandetanib—Paraesthesia—Methotrexate—psoriasis	3.84e-05	0.000216	CcSEcCtD
Vandetanib—Dyspnoea—Methotrexate—psoriasis	3.81e-05	0.000214	CcSEcCtD
Vandetanib—Dyspepsia—Methotrexate—psoriasis	3.76e-05	0.000211	CcSEcCtD
Vandetanib—Vomiting—Dexamethasone—psoriasis	3.74e-05	0.00021	CcSEcCtD
Vandetanib—Vomiting—Betamethasone—psoriasis	3.74e-05	0.00021	CcSEcCtD
Vandetanib—Decreased appetite—Methotrexate—psoriasis	3.72e-05	0.000209	CcSEcCtD
Vandetanib—Rash—Dexamethasone—psoriasis	3.7e-05	0.000208	CcSEcCtD
Vandetanib—Rash—Betamethasone—psoriasis	3.7e-05	0.000208	CcSEcCtD
Vandetanib—Dermatitis—Betamethasone—psoriasis	3.7e-05	0.000208	CcSEcCtD
Vandetanib—Dermatitis—Dexamethasone—psoriasis	3.7e-05	0.000208	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Methotrexate—psoriasis	3.69e-05	0.000207	CcSEcCtD
Vandetanib—Fatigue—Methotrexate—psoriasis	3.69e-05	0.000207	CcSEcCtD
Vandetanib—Headache—Dexamethasone—psoriasis	3.68e-05	0.000207	CcSEcCtD
Vandetanib—Headache—Betamethasone—psoriasis	3.68e-05	0.000207	CcSEcCtD
Vandetanib—Asthenia—Prednisone—psoriasis	3.67e-05	0.000206	CcSEcCtD
Vandetanib—Pain—Methotrexate—psoriasis	3.66e-05	0.000205	CcSEcCtD
Vandetanib—Pruritus—Prednisone—psoriasis	3.62e-05	0.000203	CcSEcCtD
Vandetanib—Diarrhoea—Prednisone—psoriasis	3.5e-05	0.000197	CcSEcCtD
Vandetanib—Gastrointestinal pain—Methotrexate—psoriasis	3.5e-05	0.000196	CcSEcCtD
Vandetanib—Nausea—Dexamethasone—psoriasis	3.49e-05	0.000196	CcSEcCtD
Vandetanib—Nausea—Betamethasone—psoriasis	3.49e-05	0.000196	CcSEcCtD
Vandetanib—Dizziness—Prednisone—psoriasis	3.38e-05	0.00019	CcSEcCtD
Vandetanib—Abdominal pain—Methotrexate—psoriasis	3.38e-05	0.00019	CcSEcCtD
Vandetanib—Body temperature increased—Methotrexate—psoriasis	3.38e-05	0.00019	CcSEcCtD
Vandetanib—Vomiting—Prednisone—psoriasis	3.25e-05	0.000183	CcSEcCtD
Vandetanib—Rash—Prednisone—psoriasis	3.23e-05	0.000181	CcSEcCtD
Vandetanib—Dermatitis—Prednisone—psoriasis	3.22e-05	0.000181	CcSEcCtD
Vandetanib—Headache—Prednisone—psoriasis	3.21e-05	0.00018	CcSEcCtD
Vandetanib—Asthenia—Methotrexate—psoriasis	3.07e-05	0.000172	CcSEcCtD
Vandetanib—Nausea—Prednisone—psoriasis	3.04e-05	0.000171	CcSEcCtD
Vandetanib—Pruritus—Methotrexate—psoriasis	3.03e-05	0.00017	CcSEcCtD
Vandetanib—Diarrhoea—Methotrexate—psoriasis	2.93e-05	0.000164	CcSEcCtD
Vandetanib—Dizziness—Methotrexate—psoriasis	2.83e-05	0.000159	CcSEcCtD
Vandetanib—Vomiting—Methotrexate—psoriasis	2.72e-05	0.000153	CcSEcCtD
Vandetanib—Rash—Methotrexate—psoriasis	2.7e-05	0.000151	CcSEcCtD
Vandetanib—Dermatitis—Methotrexate—psoriasis	2.69e-05	0.000151	CcSEcCtD
Vandetanib—Headache—Methotrexate—psoriasis	2.68e-05	0.00015	CcSEcCtD
Vandetanib—Nausea—Methotrexate—psoriasis	2.54e-05	0.000143	CcSEcCtD
Vandetanib—SRC—Innate Immune System—JUN—psoriasis	6.18e-06	4.48e-05	CbGpPWpGaD
Vandetanib—FYN—Hemostasis—TP53—psoriasis	6.15e-06	4.45e-05	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—TNF—psoriasis	6.14e-06	4.45e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—NFKBIA—psoriasis	6.13e-06	4.44e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—TYK2—psoriasis	6.13e-06	4.44e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—TYK2—psoriasis	6.12e-06	4.43e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—VEGFA—psoriasis	6.11e-06	4.43e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—TYK2—psoriasis	6.1e-06	4.42e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—APOE—psoriasis	6.08e-06	4.4e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—TYK2—psoriasis	6.05e-06	4.39e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—STAT3—psoriasis	6.05e-06	4.39e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—STAT3—psoriasis	6.05e-06	4.39e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—TYK2—psoriasis	6.03e-06	4.37e-05	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—IL6—psoriasis	6.03e-06	4.37e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—VEGFA—psoriasis	6e-06	4.35e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—SOCS1—psoriasis	5.98e-06	4.34e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—CXCL8—psoriasis	5.98e-06	4.33e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—CRP—psoriasis	5.95e-06	4.31e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.95e-06	4.31e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—NFKB1—psoriasis	5.95e-06	4.31e-05	CbGpPWpGaD
Vandetanib—SRC—Axon guidance—IL6—psoriasis	5.92e-06	4.29e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—NOS2—psoriasis	5.87e-06	4.26e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—IFNG—psoriasis	5.86e-06	4.25e-05	CbGpPWpGaD
Vandetanib—LYN—Developmental Biology—IL6—psoriasis	5.83e-06	4.22e-05	CbGpPWpGaD
Vandetanib—ABL1—Developmental Biology—IL6—psoriasis	5.8e-06	4.2e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—TYK2—psoriasis	5.78e-06	4.19e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—SOCS1—psoriasis	5.77e-06	4.18e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—HLA-A—psoriasis	5.76e-06	4.18e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—STAT3—psoriasis	5.75e-06	4.17e-05	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—IL6—psoriasis	5.74e-06	4.16e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—IFNG—psoriasis	5.74e-06	4.16e-05	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—IL6—psoriasis	5.74e-06	4.16e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—NFKB1—psoriasis	5.71e-06	4.14e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—IFNG—psoriasis	5.71e-06	4.14e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—TYK2—psoriasis	5.7e-06	4.13e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—HLA-DRB1—psoriasis	5.7e-06	4.13e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—NOS2—psoriasis	5.66e-06	4.1e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—CD4—psoriasis	5.66e-06	4.1e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—IFNG—psoriasis	5.65e-06	4.09e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—APOE—psoriasis	5.6e-06	4.06e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—TYK2—psoriasis	5.57e-06	4.04e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—JUN—psoriasis	5.56e-06	4.03e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—CD4—psoriasis	5.54e-06	4.02e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—CD4—psoriasis	5.52e-06	4e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TYK2—psoriasis	5.5e-06	3.99e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—ICAM1—psoriasis	5.47e-06	3.97e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—CXCL8—psoriasis	5.47e-06	3.96e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—TP53—psoriasis	5.46e-06	3.96e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—CD4—psoriasis	5.46e-06	3.95e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—NFKBIA—psoriasis	5.43e-06	3.93e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—APOE—psoriasis	5.38e-06	3.9e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—NFKB1—psoriasis	5.35e-06	3.88e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—CXCL8—psoriasis	5.33e-06	3.86e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TYK2—psoriasis	5.31e-06	3.85e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—LEP—psoriasis	5.3e-06	3.84e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—APOE—psoriasis	5.3e-06	3.84e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—CXCL8—psoriasis	5.27e-06	3.82e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—IL6—psoriasis	5.26e-06	3.81e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—TNF—psoriasis	5.24e-06	3.8e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—CD4—psoriasis	5.23e-06	3.79e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—TYK2—psoriasis	5.21e-06	3.78e-05	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—IL6—psoriasis	5.19e-06	3.76e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—APOE—psoriasis	5.19e-06	3.76e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—LEP—psoriasis	5.19e-06	3.76e-05	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—IL6—psoriasis	5.15e-06	3.73e-05	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—IL6—psoriasis	5.12e-06	3.71e-05	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—TP53—psoriasis	5.12e-06	3.71e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—LEP—psoriasis	5.11e-06	3.7e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—APOE—psoriasis	5.11e-06	3.7e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—TYK2—psoriasis	5.11e-06	3.7e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—SOCS1—psoriasis	5.1e-06	3.7e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—JUN—psoriasis	5.08e-06	3.68e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—JUN—psoriasis	5.07e-06	3.67e-05	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—IL6—psoriasis	5.07e-06	3.67e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—CD4—psoriasis	5.04e-06	3.65e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—TYK2—psoriasis	5.02e-06	3.64e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—NOS2—psoriasis	5.01e-06	3.63e-05	CbGpPWpGaD
Vandetanib—BLK—Immune System—IL6—psoriasis	5e-06	3.62e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—IL6—psoriasis	5e-06	3.62e-05	CbGpPWpGaD
Vandetanib—FGR—Immune System—IL6—psoriasis	4.98e-06	3.61e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—CXCL8—psoriasis	4.97e-06	3.6e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—JUN—psoriasis	4.96e-06	3.59e-05	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—IL6—psoriasis	4.96e-06	3.59e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—JUN—psoriasis	4.95e-06	3.59e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—NFKBIA—psoriasis	4.94e-06	3.58e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—JUN—psoriasis	4.94e-06	3.58e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—APOE—psoriasis	4.93e-06	3.57e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—JUN—psoriasis	4.9e-06	3.55e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—NFKB1—psoriasis	4.89e-06	3.55e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—JUN—psoriasis	4.88e-06	3.54e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IFNG—psoriasis	4.88e-06	3.54e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PPARG—psoriasis	4.88e-06	3.54e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—NFKB1—psoriasis	4.88e-06	3.53e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—VEGFA—psoriasis	4.86e-06	3.52e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—NFKBIA—psoriasis	4.84e-06	3.51e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—TYK2—psoriasis	4.81e-06	3.49e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—STAT3—psoriasis	4.81e-06	3.48e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—CXCL8—psoriasis	4.79e-06	3.47e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—NFKB1—psoriasis	4.77e-06	3.46e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—NFKB1—psoriasis	4.77e-06	3.46e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—NFKBIA—psoriasis	4.76e-06	3.45e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—NFKB1—psoriasis	4.75e-06	3.44e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—NFKB1—psoriasis	4.72e-06	3.42e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—CD4—psoriasis	4.71e-06	3.42e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—IFNG—psoriasis	4.7e-06	3.41e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—NFKB1—psoriasis	4.7e-06	3.41e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—TYK2—psoriasis	4.64e-06	3.36e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—CXCL8—psoriasis	4.63e-06	3.35e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—CD4—psoriasis	4.62e-06	3.35e-05	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—IL6—psoriasis	4.58e-06	3.32e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—CD4—psoriasis	4.54e-06	3.29e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—TP53—psoriasis	4.53e-06	3.28e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—JUN—psoriasis	4.45e-06	3.23e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—TYK2—psoriasis	4.45e-06	3.22e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—VEGFA—psoriasis	4.44e-06	3.22e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—LEP—psoriasis	4.41e-06	3.2e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—APOE—psoriasis	4.41e-06	3.2e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—STAT3—psoriasis	4.4e-06	3.19e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—STAT3—psoriasis	4.38e-06	3.18e-05	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—IL6—psoriasis	4.38e-06	3.17e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—CD4—psoriasis	4.35e-06	3.15e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—VEGFA—psoriasis	4.33e-06	3.14e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—JUN—psoriasis	4.3e-06	3.12e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PPARG—psoriasis	4.29e-06	3.11e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—STAT3—psoriasis	4.29e-06	3.11e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—NFKB1—psoriasis	4.29e-06	3.11e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—STAT3—psoriasis	4.28e-06	3.11e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—VEGFA—psoriasis	4.28e-06	3.1e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—STAT3—psoriasis	4.27e-06	3.09e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—APOE—psoriasis	4.25e-06	3.08e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—LEP—psoriasis	4.25e-06	3.08e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—STAT3—psoriasis	4.24e-06	3.07e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—IL6—psoriasis	4.23e-06	3.06e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—IL6—psoriasis	4.23e-06	3.06e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—STAT3—psoriasis	4.22e-06	3.06e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—JUN—psoriasis	4.22e-06	3.06e-05	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—IL6—psoriasis	4.22e-06	3.06e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—CD4—psoriasis	4.19e-06	3.04e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—IFNG—psoriasis	4.16e-06	3.02e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—NFKB1—psoriasis	4.14e-06	3e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—NFKBIA—psoriasis	4.11e-06	2.98e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—TYK2—psoriasis	4.11e-06	2.98e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—JUN—psoriasis	4.07e-06	2.95e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—NFKB1—psoriasis	4.06e-06	2.94e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—VEGFA—psoriasis	4.05e-06	2.93e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TYK2—psoriasis	4.05e-06	2.93e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—STAT3—psoriasis	4.05e-06	2.93e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—CD4—psoriasis	4.02e-06	2.91e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—IL6—psoriasis	4.02e-06	2.91e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—NFKBIA—psoriasis	3.96e-06	2.87e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TYK2—psoriasis	3.96e-06	2.87e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CAT—psoriasis	3.91e-06	2.84e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—NFKB1—psoriasis	3.91e-06	2.84e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TYK2—psoriasis	3.9e-06	2.83e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—STAT3—psoriasis	3.9e-06	2.83e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—STAT3—psoriasis	3.85e-06	2.79e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—APOE—psoriasis	3.77e-06	2.73e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—LEP—psoriasis	3.77e-06	2.73e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—VEGFA—psoriasis	3.76e-06	2.72e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—IL6—psoriasis	3.73e-06	2.71e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—STAT3—psoriasis	3.72e-06	2.7e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—CD4—psoriasis	3.71e-06	2.69e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—TP53—psoriasis	3.67e-06	2.66e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—STAT3—psoriasis	3.65e-06	2.64e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—JUN—psoriasis	3.6e-06	2.61e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—STAT3—psoriasis	3.57e-06	2.59e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CXCL8—psoriasis	3.52e-06	2.55e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—STAT3—psoriasis	3.52e-06	2.55e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NFKBIA—psoriasis	3.51e-06	2.54e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—NFKB1—psoriasis	3.46e-06	2.51e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CXCL8—psoriasis	3.45e-06	2.5e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CARM1—psoriasis	3.44e-06	2.49e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CXCL8—psoriasis	3.4e-06	2.46e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TYK2—psoriasis	3.37e-06	2.44e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—STAT3—psoriasis	3.37e-06	2.44e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—IL6—psoriasis	3.36e-06	2.43e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—TP53—psoriasis	3.36e-06	2.43e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—JUN—psoriasis	3.28e-06	2.37e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—TP53—psoriasis	3.27e-06	2.37e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TYK2—psoriasis	3.25e-06	2.35e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—STAT3—psoriasis	3.25e-06	2.35e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—TP53—psoriasis	3.23e-06	2.34e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—JUN—psoriasis	3.21e-06	2.32e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—JUN—psoriasis	3.16e-06	2.29e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—NFKB1—psoriasis	3.15e-06	2.28e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—STAT3—psoriasis	3.11e-06	2.26e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—NFKB1—psoriasis	3.09e-06	2.24e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—IL6—psoriasis	3.07e-06	2.23e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—IL6—psoriasis	3.06e-06	2.22e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—TP53—psoriasis	3.06e-06	2.22e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—APOE—psoriasis	3.04e-06	2.2e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—NFKB1—psoriasis	3.04e-06	2.2e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—IL6—psoriasis	3e-06	2.17e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—IL6—psoriasis	2.99e-06	2.17e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—IL6—psoriasis	2.98e-06	2.16e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—IL6—psoriasis	2.96e-06	2.15e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—IL6—psoriasis	2.95e-06	2.14e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TP53—psoriasis	2.94e-06	2.13e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CXCL8—psoriasis	2.93e-06	2.13e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TYK2—psoriasis	2.87e-06	2.08e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—STAT3—psoriasis	2.87e-06	2.08e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—VEGFA—psoriasis	2.86e-06	2.07e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TP53—psoriasis	2.84e-06	2.06e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—STAT3—psoriasis	2.83e-06	2.05e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CXCL8—psoriasis	2.83e-06	2.05e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—IL6—psoriasis	2.83e-06	2.05e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—VEGFA—psoriasis	2.8e-06	2.03e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—IL6—psoriasis	2.79e-06	2.02e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—STAT3—psoriasis	2.77e-06	2.01e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—VEGFA—psoriasis	2.76e-06	2e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—STAT3—psoriasis	2.73e-06	1.98e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—JUN—psoriasis	2.73e-06	1.98e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—IL6—psoriasis	2.72e-06	1.97e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—IL6—psoriasis	2.69e-06	1.95e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PPARG—psoriasis	2.65e-06	1.92e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—JUN—psoriasis	2.63e-06	1.9e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—NFKB1—psoriasis	2.63e-06	1.9e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—IL6—psoriasis	2.6e-06	1.88e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IL6—psoriasis	2.55e-06	1.85e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—NFKB1—psoriasis	2.53e-06	1.83e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CXCL8—psoriasis	2.5e-06	1.81e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—IL6—psoriasis	2.5e-06	1.81e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—IL6—psoriasis	2.46e-06	1.78e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—VEGFA—psoriasis	2.38e-06	1.73e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—STAT3—psoriasis	2.36e-06	1.71e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—IL6—psoriasis	2.35e-06	1.71e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—JUN—psoriasis	2.33e-06	1.69e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—VEGFA—psoriasis	2.3e-06	1.66e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—STAT3—psoriasis	2.27e-06	1.65e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—IL6—psoriasis	2.27e-06	1.64e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NFKB1—psoriasis	2.24e-06	1.62e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL6—psoriasis	2.17e-06	1.58e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TP53—psoriasis	2.16e-06	1.57e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TP53—psoriasis	2.12e-06	1.53e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CAT—psoriasis	2.11e-06	1.53e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TP53—psoriasis	2.08e-06	1.51e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—VEGFA—psoriasis	2.03e-06	1.47e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—STAT3—psoriasis	2.01e-06	1.46e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—IL6—psoriasis	2.01e-06	1.46e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IL6—psoriasis	1.98e-06	1.43e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IL6—psoriasis	1.94e-06	1.4e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IL6—psoriasis	1.91e-06	1.38e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TP53—psoriasis	1.8e-06	1.3e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TP53—psoriasis	1.74e-06	1.26e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL6—psoriasis	1.65e-06	1.19e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—APOE—psoriasis	1.64e-06	1.19e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL6—psoriasis	1.59e-06	1.15e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TP53—psoriasis	1.54e-06	1.11e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PPARG—psoriasis	1.43e-06	1.04e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL6—psoriasis	1.41e-06	1.02e-05	CbGpPWpGaD
